Skip to main content
. Author manuscript; available in PMC: 2018 Aug 19.
Published in final edited form as: Nat Struct Mol Biol. 2018 Feb 19;25(3):217–224. doi: 10.1038/s41594-018-0031-y

Figure 5. Chemically modifying tunicamycin can introduce ligand selectivity between hGPT and MraYAA.

Figure 5

a, Chemical structures of tunicamycin and its MurNAc derivative. The substructure highlighted in red differs from tunicamycin, being a MurNAc-like moiety rather than a GlcNAc moiety as in tunicamycin. b, IC50 measurements of tunicamycin and its MurNAc analog (tunicamycin-MurNac) with hGPT and MraYAA, respectively. hGPT is much less inhibited by tunicamycin-MurNAc than tunicamycin, while MraY appears to be similarly inhibited by both tunicamycin and tunicamycin-MurNAc. The IC50 for hGPT with tunicamycin is ~9 nM; for hGPT with tunicamycin-MurNAc is ~15 μM; for MraYAA with tunicamycin is ~450 nM; for MraYAA with tunicamycin-MurNAc is ~640 nM. Each IC50 value was determined using the TLC-based phosphoglycosyl transferase assay. Data are shown as the mean of triplicate measurements (technical replicates) ± s.e.m.